04/05/2026 22:10
|
Medical, Health & Aged Care
* MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo
* Improvements observed across key symptoms,...